Abstracts tagged "Pediatric rheumatology"

Abstract Number: 027 • 2020 Pediatric Rheumatology Symposium
Clinical Features and Outcomes in Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature (CANDLE) Syndrome: Before and After JAK-inhibition
Sofia Torreggiani¹, Pascal Pillet ², Fabiano de Oliveira Poswar ³, Anna Kozlova ⁴, Anna Shcherbina ⁴, Marietta De Guzman ⁵, Jacob Mitchell ⁶, Gina A. Montealegre Sanchez ⁷, Katherine Townsend ⁸, Kim Johnson ⁹, Adriana Almeida de Jesus ¹⁰ and Raphaela Goldbach-Mansky ¹¹, ¹National Institutes of Health, Bethesda, ²Bordeaux Cedex, France, ³Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, ⁴Center for Pediatric Hematology, Oncology, Immunology, Moscow, Russia, ⁵Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, ⁶NIAID, NIH, Bethesda, ⁷NIH/ NIAID, Rockville, ⁸NIH, ⁹NIH, NIAID, Bethesda, ¹⁰NIAID, NIH, Silver Spring, ¹¹NIH/NIAID, Potomac
Background/Purpose: Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy And Elevated Temperature (CANDLE) Syndrome is an autoinflammatory interferonopathy caused by mutations in the genes encoding for components…
Abstract Number: 083 • 2020 Pediatric Rheumatology Symposium
Worsening Disease Activity and Inability to Taper Corticosteroids in an Ethnically Diverse Cohort of Pediatric-Onset Lupus Patients After Transition to Adult Care
Marla Guzman¹, Anne Eberhard ¹ and Joyce Hui-Yuen ², ¹Cohen Children's Medical Center, Lake Success, ²Cohen Children's Medical Center, New Hyde Park
Background/Purpose: Transition of pediatric lupus (pSLE) patients from pediatric to adult rheumatology care is historically difficult and challenging. We aim to investigate disease activity and…
Abstract Number: 032 • 2020 Pediatric Rheumatology Symposium
The Impact of Psychiatric Diagnosis and Treatment on Medication Adherence in Youth with Systemic Lupus Erythematosus
Joyce Chang¹, Alaina Davis ², Marisa Klein-Gitelman ³, Zuleyha Cidav ⁴, David Mandell ⁵ and Andrea Knight ⁶, ¹Children's Hospital of Philadelphia, Philadelphia, ²Monroe Carell Jr. Children’s Hospital at Vanderbilt, Nashville, Tennessee, ³Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, ⁴University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, ⁵Perelman School of Medicine at the University of Pennsylvania, Philadelphia, ⁶SickKids Research Institute, Toronto, Canada
Background/Purpose: Youth with systemic lupus erythematosus (SLE) experience significant health care burden and high rates of psychiatric disorders. Optimizing medication adherence is critical for preventing…
Abstract Number: 102 • 2020 Pediatric Rheumatology Symposium
Implications of Positive Tests for ANCA in a Pediatric Population
Karen James¹, Peter Merkel ² and Aimee Hersh ³, ¹University of Utah, 84113, Utah, ²University of Pennsylvania, Philadelphia, ³University of Utah Primary Children's Hospital, Salt Lake City
Background/Purpose: Testing for ANCA, particularly performed by ELISA (anti-MPO/PR3) is highly sensitive and specific for ANCA-associated vasculitis (AAV). However ANCA testing may be used in…
Abstract Number: 033 • 2020 Pediatric Rheumatology Symposium
Parental Adverse Childhood Experience (ACE) Exposure Is Predictive of Active Lupus in Pediatric Patients
Michael Nelson¹, Nancy Correa ², Ashley Butler ¹, Marietta De Guzman ³, Bethanie Van Horne ¹ and Christopher Greeley ¹, ¹Baylor College of Medicine, Houston, ²Texas Children's Hospital, Houston, ³Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
Background/Purpose: Adverse Childhood Experiences (ACEs) have been recognized for more than two decades as risk factors for poor health outcomes in adults. Nevertheless, the impact…
Abstract Number: 106 • 2020 Pediatric Rheumatology Symposium
Childhood-onset Takayasu Arteritis: A Single Center Case Series of Atypical and Varied Presentations
Uptej Khalsa¹ and Imelda Balboni ¹, ¹Stanford University, Palo Alto, California
Background/Purpose: Childhood-onset Takayasu arteritis is a rare inflammatory vessel disease that predominantly affects the aorta and its major branches. Clinical presentation at disease onset can…
Abstract Number: 035 • 2020 Pediatric Rheumatology Symposium
The Childhood and Rheumatology Research Alliance Systemic Lupus Erythematosus and Related Disorders Cohort
Stacy Ardoin¹, Stephen Balevic ², Aimee Hersh ³, Yukiko Kimura ⁴, Andrea Knight ⁵, Laura Schanberg ⁶, Mary Beth Son ⁷ and Timothy Beukelman ⁸ for the CARRA investigators, ¹Nationwide Children's Hospital, Columbus, ²Duke University, Hillsborough, ³University of Utah Primary Children's Hospital, Salt Lake City, ⁴Hackensack Meridian School of Medicine, Hackensack, ⁵SickKids Research Institute, Toronto, Canada, ⁶Duke Children's Hospital & Health Center, Durham, North Carolina, ⁷Boston Children's Hospital, Boston, Massachusetts, ⁸University of Alabama at Birmingham, Birmingham
Background/Purpose: Optimal therapy in childhood onset systemic lupus erythematosus (SLE) lack sufficient data to support clinical decision making. To address this knowledge gap, the Childhood…
Abstract Number: 116 • 2020 Pediatric Rheumatology Symposium
Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry
Natalie Shiff¹, Aimee Lougee ², Roland Matsouaka ², David Collier ³, Yukiko Kimura ⁴, Dax Rumsey ⁵, Jennifer Schenfeld ⁶, Scott Stryker ⁷, Marinka Twilt ⁸ and Timothy Beukelman ⁹, ¹Florida, Gainesville, ²Duke University, Durham, ³Amgen, Thousand Oaks, ⁴Hackensack Meridian School of Medicine, Hackensack, ⁵University of Alberta, Edmonton, Canada, ⁶Amgen, Long Beach, ⁷Amgen, Inc, San Francisco, ⁸Alberta Children's Hospital, Calgary, Canada, ⁹University of Alabama at Birmingham, Birmingham
Background/Purpose: Etanercept (ETN) is an anti-tumor necrosis factor (anti-TNF) therapy that is FDA approved for the treatment of polyarticular juvenile idiopathic arthritis (JIA). This study…
Abstract Number: 040 • 2020 Pediatric Rheumatology Symposium
Patient-Proxy Agreement on Mental Health and Neuropsychological Symptoms Among Youth with Juvenile Fibromyalgia Syndrome
Sabrina Gmuca¹, Maitry Sonagra ², Rui Xiao ³, Nina Thomas ⁴, Kimberly S. Miller ⁴, Jami F. Young ⁴, Pamela Weiss ⁴, David D. Sherry ⁴ and Jeffrey S. Gerber ⁴, ¹Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, ²Children's Hospital of Philadelphia, Cherry Hill, ³University of Pennsylvania, Philadelphia, ⁴Children's Hospital of Philadelphia, Philadelphia
Background/Purpose: Adolescents with juvenile fibromyalgia syndrome (JFMS) present with a myriad of mental health and neuropsychological symptoms, including dyscognition (“brain fog”); however, patient-proxy agreement on…
Abstract Number: 126 • 2020 Pediatric Rheumatology Symposium
Cyclophosphamide as Rescue Therapy for Kawasaki Disease with Peripheral Vascular Disease: A Single Center Experience
Ugo Awa¹, Monica Bray ² and Marietta De Guzman ³, ¹Baylor College of Medicine, Houston, ²Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, ³Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
Background/Purpose: Kawasaki Disease (KD) is the most common systemic vasculitis affecting children 5 years and younger. With coronary vessel involvement, KD is now the most…
Abstract Number: 043 • 2020 Pediatric Rheumatology Symposium
Resolution of Coronary Artery Changes in Patients with Refractory Kawasaki Disease with Prolonged Course of Infliximab: A Case Series
Shelley Shi¹ and Anusha Ramanathan ¹, ¹Kaiser Permanente Los Angeles, Los Angeles, California
Background/Purpose: Treatment for patients with Kawasaki Disease (KD) refractory to standard therapy is controversial. Most experts recommend a second dose of IVIG [1], and for…
Abstract Number: 131 • 2020 Pediatric Rheumatology Symposium
Practice Patterns for Consulting Pediatric Rheumatology in a Large Pediatric Intensive Care Unit
Jennifer Rammel¹, Satid Thammasitboon ², Jorge Coss Bu ² and Eyal Muscal ³, ¹Section of Nephrology and Rheumatology, Department of Pediatrics, University of Florida Health Jacksonville, Jacksonville, Florida, ²Baylor College of Medicine, Houston, Texas, ³Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, houston
Background/Purpose: Pediatric Rheumatology (PR) is a young and still evolving subspecialty. In addition to traditional rheumatic diseases, there has been an increased prevalence of emerging…
Abstract Number: 045 • 2020 Pediatric Rheumatology Symposium
No-Shows: a Search for Modifiable Risk Factors
Samantha Ong ¹, Xujia Li ¹ and Austin Dalrymple², ¹Saint Louis University School of Medicine, St. Louis, ²Saint Louis University School of Medicine, Saint Louis, Missouri
Background/Purpose: Missed ambulatory visits, or “no-shows,” limit patient access, increase costs, occupy provider time, and lead to worse patient outcomes. Only a few studies have…
Abstract Number: 132 • 2020 Pediatric Rheumatology Symposium
Clinical Characteristics and Outcomes of Critically Ill Children Requiring Rheumatology Consultation in a Large Intensive Care Unit
Jennifer Rammel¹, Kristen Staggers ², Satid Thammasitboon ², Jorge Coss Bu ², Amanda Brown ³ and Eyal Muscal ⁴, ¹Section of Nephrology and Rheumatology, Department of Pediatrics, University of Florida Health Jacksonville, Jacksonville, Florida, ²Baylor College of Medicine, Houston, Texas, ³Baylor College of Medicine, Houston, ⁴Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, houston
Background/Purpose: Pediatric rheumatology has been an evolving subspecialty over the last few decades with a continued increase in the both the number and severity of…
Abstract Number: 050 • 2020 Pediatric Rheumatology Symposium
Long Term Safety of Biologics and Biosimilars in Pediatric Rheumatic Diseases: An Experience from a Single North Indian Centre
MANJARI AGARWAL ¹, Sujata Sawhney² and Anju Singh ³, ¹Sir Ganga Ram Hospital, NEW DELHI, Delhi, India, ²Sir ganga ram hospital, Sector 37 noida, Uttar Pradesh, India, ³Sir Ganga Ram Hospital, delhi, India
Background/Purpose: The use of biologic response modifiers(BRMs) is associated with an increased risk of infections.We also use biosimilars for two reasons:1. originator not available, like…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].